Published Date : Oct 17, 2016
Albany, NY, Oct 17, 2016: The research report, titled “Global Myelodysplastic Syndrome Market 2015-2019,” offers an in-depth understanding of the drivers and restraints that are shaping the future of the global myelodysplastic syndrome market. The document has been collaborated using primary and secondary research methodologies. The information presented in the report has been curated from journals, interviews, magazines, conferences, and white papers to enable the readers to formulate well-informed business decisions.
According to the research report, the global myelodysplastic syndrome market is expected to expand at a CAGR of 9.93% between 2015 and 2019. The increasing pool of geriatrics has been identified as the primary growth for the global myelodysplastic syndrome market. The disease is predominantly age-related and is known to affect people who are above the age of 60. Some of the other factors responsible for the rise of this market are an increasing number of smokers, high levels of exposure to radiation, genetic mutations, contact with chemicals such as benzene, and chemotherapy. The vast unmet medical needs, especially in the developing regions of the world, are also anticipated to favor the global market. The availability of diagnostic tools is also likely to provide ample of growth opportunities to the global market in the near future.
Despite the steady market drivers, the market is likely to be stymied by the growing demand for generic drugs. Their affordability and effectiveness are making them popular amongst patients. Furthermore, the side effects of drugs for myelodysplastic syndrome are also hampering the growth of this market. On the whole, the high cost of drugs and their adverse side effects are the two important factors challenging the growth of the global market.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/527262
Analysts predict that negative aspects of the market dynamics in the global myelodysplastic syndrome market can be overcome with several opportunities being offered through multiple mediums. For instance, the rising public awareness about the syndrome is anticipated to change the way this condition is being treated in the near future. Furthermore, patient assistance programs and increasing research and development activities are also anticipated to offer several lucrative opportunities to the global market.
Some of the key players operating in the global myelodysplastic syndrome market are Celator Pharmaceuticals, Celgene, Mirati Therapeutics, Novartis, Otsuka, BioLineRx, Kiadis Pharma, and KaloBios Pharmaceuticals. The research report profiles these players and provides a thorough reports of the competitive landscape present in the global myelodysplastic syndrome market. It also includes a Porter’s five forces reports, which determines the threat of new entrants, the bargaining power of suppliers and buyers, and the intensity of the competitive rivalry. The document includes a comprehensive outlook of the business and marketing strategies to give its readers a granular view of the overall market for the near future
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org